A nomogram based on pretreatment clinical parameters for the prediction of inadequate biochemical response in primary biliary cholangitis

被引:9
|
作者
Tian, Siyuan [1 ]
Liu, Yansheng [1 ]
Sun, Keshuai [1 ]
Zhou, Xia [1 ]
Ma, Shuoyi [1 ]
Zhang, Miao [1 ]
Zhou, Xinmin [1 ]
Wang, Lu [1 ,2 ]
Han, Ying [1 ]
机构
[1] Fourth Mil Med Univ, Inst Digest Dis, Xijing Hosp, Xian 710032, Shaanxi, Peoples R China
[2] Fourth Mil Med Univ, Dept Biochem & Mol Biol, State Key Lab Canc Biol, Xian, Peoples R China
基金
中国国家自然科学基金; 中国博士后科学基金;
关键词
autoimmune liver disease; biochemical response; nomogram; primary biliary cholangitis; ursodeoxycholic acid; PLACEBO-CONTROLLED TRIAL; LONG-TERM PROGNOSIS; URSODEOXYCHOLIC ACID; CIRRHOSIS; FIBROSIS; OUTCOMES; THERAPY;
D O I
10.1002/jcla.23501
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background Ursodeoxycholic acid (UDCA) has been widely recommended as the first-line drug for primary biliary cholangitis (PBC) in the current guidelines. However, its therapeutic effects are poor in nearly one-third of patients. The early identification and intervention of these patients is crucial for delaying disease progression. Therefore, we explored risk factors for inadequate biochemical response and constructed a nomogram to predict the potential risk. Methods We enrolled 356 patients and randomly divided them into training (70%) and validation groups (30%). We defined inadequate biochemical response as the study endpoint. Logistic analysis was used to identify the independent predictors of poor biochemical response. Based on these factors, a predictive nomogram was finally constructed. Then, discrimination and calibration were evaluated by internal validation. Additionally, the association between the model predictions and prognosis was further analyzed. Results Female sex, and albumin and bilirubin concentrations were identified as risk factors, and a nomogram was built based on these factors. The areas under the ROC curves of the training and validation groups were 0.809 and 0.791, respectively. Moreover, calibration curves showed that predictions of the nomogram had good concordance with the actual outcomes. The correlation analysis demonstrated that PBC patients with a high probability of a suboptimal biochemical response were more likely to have adverse outcomes. Conclusion We constructed a nomogram, which can accurately predict the risk of inadequate biochemical response to UDCA, facilitating the early screening of high-risk patients with PBC who should be prioritized for additional therapy.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response
    Perez, Carla F. Murillo
    Hirschfield, Gideon M.
    Corpechot, Christophe
    Floreani, Annarosa
    Mayo, Marlyn J.
    van der Meer, Adriaan
    Ponsioen, Cyriel Y.
    Lammers, Willem J.
    Pares, Albert
    Invernizzi, Pietro
    Carbone, Marco
    Battezzati, Pier Maria
    Nevens, Frederik
    Kowdley, Kris V.
    Thorburn, Douglas
    Mason, Andrew L.
    Trivedi, Palak J.
    Lindor, Keith D.
    Bruns, Tony
    Dalekos, George N.
    Gatselis, Nikolaos K.
    Verhelst, Xavier
    Janssen, Harry L. A.
    Hansen, Bettina E.
    Gulamhusein, Aliya
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2019, 50 (10) : 1127 - 1136
  • [22] Application of the Latest Advances in Evidence-Based Medicine in Primary Biliary Cholangitis
    Kowdley, Kris. V. V.
    Bowlus, Christopher. L. L.
    Levy, Cynthia
    Mayo, Marlyn. J. J.
    Pratt, Daniel. S. S.
    Vuppalanchi, Raj
    Younossi, Zobair. M. M.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (02) : 232 - 242
  • [23] Evidence for the association between IgG-antimitochondrial antibody and biochemical response to ursodeoxycholic acid treatment in primary biliary cholangitis
    Tang, Libo
    Zhong, Ruihua
    He, Xuanqiu
    Wang, Weibin
    Liu, Jinhong
    Zhu, Youfu
    Li, Yongyin
    Hou, Jinlin
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2017, 32 (03) : 659 - 666
  • [24] Symptom Burden and Treatment Response in Patients with Primary Biliary Cholangitis (PBC)
    Kaps, Leonard
    Grambihler, Annette
    Yemane, Bethlehem
    Nagel, Michael
    Labenz, Christian
    Ploch, Pascal
    Michel, Maurice
    Galle, Peter R.
    Woerns, Marcus-Alexander
    Schattenberg, Joern M.
    DIGESTIVE DISEASES AND SCIENCES, 2020, 65 (10) : 3006 - 3013
  • [25] The association of histological progression with biochemical response to ursodeoxycholic acid in primary biliary cholangitis
    Namisaki, Tadashi
    Fujinaga, Yukihisa
    Moriya, Kei
    Yoshiji, Hitoshi
    HEPATOLOGY RESEARCH, 2021, 51 (01) : 31 - 38
  • [26] Surrogate Endpoints for Optimal Therapeutic Response to UDCA in Primary Biliary Cholangitis
    van Buuren, Henk R.
    Lammers, Willem J.
    Harms, Maren H.
    Hansen, Bettina E.
    DIGESTIVE DISEASES, 2015, 33 : 118 - 124
  • [27] Gut dysbiosis associated with clinical prognosis of patients with primary biliary cholangitis
    Furukawa, Masanori
    Moriya, Kei
    Nakayama, Jiro
    Inoue, Takako
    Momoda, Rie
    Kawaratani, Hideto
    Namisaki, Tadashi
    Sato, Shinya
    Douhara, Akitoshi
    Kaji, Kosuke
    Kitade, Mitsuteru
    Shimozato, Naotaka
    Sawada, Yasuhiko
    Saikawa, Soichiro
    Takaya, Hiroaki
    Kitagawa, Koh
    Akahane, Takemi
    Mitoro, Akira
    Yamao, Junichi
    Tanaka, Yasuhito
    Yoshiji, Hitoshi
    HEPATOLOGY RESEARCH, 2020, 50 (07) : 840 - 852
  • [28] Clinical Management of Primary Biliary Cholangitis-Strategies and Evolving Trends
    Gao, Lixia
    Wang, Li
    Woo, Elena
    He, XiaoSong
    Yang, GaoXiang
    Bowlus, Christopher
    Leung, Patrick S. C.
    Gershwin, M. Eric
    CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2020, 59 (02) : 175 - 194
  • [29] Investigational drugs in phase II clinical trials for primary biliary cholangitis
    Silveira, Marina G.
    Lindor, Keith D.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2017, 26 (10) : 1115 - 1121
  • [30] Machine learning prediction model for treatment responders in patients with primary biliary cholangitis
    Kimura, Naruhiro
    Takahashi, Kazuya
    Setsu, Toru
    Goto, Shu
    Miida, Suguru
    Takeda, Nobutaka
    Kojima, Yuichi
    Arao, Yoshihisa
    Hayashi, Kazunao
    Sakai, Norihiro
    Watanabe, Yusuke
    Abe, Hiroyuki
    Kamimura, Hiroteru
    Sakamaki, Akira
    Yokoo, Takeshi
    Kamimura, Kenya
    Tsuchiya, Atsunori
    Terai, Shuji
    JGH OPEN, 2023, 7 (06): : 431 - 438